Pelvic vein thrombosis in patients with pelvic venous disorders.

Phlebology Pub Date : 2024-09-01 Epub Date: 2024-05-20 DOI:10.1177/02683555241256264
Sergey G Gavrilov, Yekaterina P Moskalenko, Anatoly V Karalkin, Alexander V Alenichev
{"title":"Pelvic vein thrombosis in patients with pelvic venous disorders.","authors":"Sergey G Gavrilov, Yekaterina P Moskalenko, Anatoly V Karalkin, Alexander V Alenichev","doi":"10.1177/02683555241256264","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the incidence of pelvic vein thrombosis (PVT) and outcomes of anticoagulant therapy for PVT in patients with pelvic venous disorders (PeVDs).</p><p><strong>Methods: </strong>This prospective cohort study included 588 female patients with PeVDs underwent clinical examination followed by duplex ultrasound of the pelvic veins in 2021-2023. Patients with PVT were administered with anticoagulant therapy in an outpatient setting using low molecular weight heparins at a therapeutic dose.</p><p><strong>Results: </strong>PVT was detected in 7.6% of patients with PeVDs and was symptomatic in 28.8% of them. The majority of asymptomatic patients had thrombosis in only one of the parametrial veins (90.6%). Anticoagulant therapy resulted in the PVT symptoms relief in all patients within 10 days and recanalization of the pelvic veins in 1-3 months.</p><p><strong>Conclusion: </strong>In our study, PVT was diagnosed in 7.6% of patients with PeVDs. Anticoagulant therapy is effective and safe in resolving PVT symptoms.</p>","PeriodicalId":94350,"journal":{"name":"Phlebology","volume":" ","pages":"534-542"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02683555241256264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess the incidence of pelvic vein thrombosis (PVT) and outcomes of anticoagulant therapy for PVT in patients with pelvic venous disorders (PeVDs).

Methods: This prospective cohort study included 588 female patients with PeVDs underwent clinical examination followed by duplex ultrasound of the pelvic veins in 2021-2023. Patients with PVT were administered with anticoagulant therapy in an outpatient setting using low molecular weight heparins at a therapeutic dose.

Results: PVT was detected in 7.6% of patients with PeVDs and was symptomatic in 28.8% of them. The majority of asymptomatic patients had thrombosis in only one of the parametrial veins (90.6%). Anticoagulant therapy resulted in the PVT symptoms relief in all patients within 10 days and recanalization of the pelvic veins in 1-3 months.

Conclusion: In our study, PVT was diagnosed in 7.6% of patients with PeVDs. Anticoagulant therapy is effective and safe in resolving PVT symptoms.

盆腔静脉疾病患者的盆腔静脉血栓形成。
目的评估盆腔静脉疾病(PeVDs)患者盆腔静脉血栓形成(PVT)的发生率和抗凝治疗PVT的效果:这项前瞻性队列研究纳入了588名女性盆腔静脉疾病患者,她们在2021-2023年间接受了临床检查和盆腔静脉双相超声检查。PVT患者在门诊接受治疗剂量的低分子量肝素抗凝治疗:结果:7.6%的 PeVDs 患者被检测出 PVT,其中 28.8% 的患者有症状。大多数无症状患者只有一条宫旁静脉出现血栓(90.6%)。抗凝治疗使所有患者的 PVT 症状在 10 天内缓解,盆腔静脉在 1-3 个月内重新闭塞:结论:在我们的研究中,7.6% 的 PeVDs 患者被确诊为 PVT。结论:在我们的研究中,7.6% 的 PeVDs 患者被确诊为 PVT,抗凝治疗在缓解 PVT 症状方面既有效又安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信